Why D&O insurance is pricier for tech and biotech firms


For tech and biotech companies headed for the IPO window, Directors & Officers (D&O) insurance is a critical risk management tool, but securing D&O coverage is increasingly difficult and more expensive than ever to retain.

In fact, a series of factors has transformed the current environment into the most challenging D&O insurance market since the dot.com bust.

Securities class-action lawsuits are the root cause of the problem. More bearishly, the outlook for D&O insurance isn’t likely to improve…

Previous How to create a construction company legacy
Next Ask the Accountant: What are the most common business valuation mistakes and how can I avoid them?

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *